Sobi
Sobi

Sobi Grows Product Portfolio With 2nd Deal

Swedish Orphan Biovitrum AB (STO: SOBI), an international specialty healthcare company dedicated to rare diseases, announced its acquisition of Dova Pharmaceuticals, Inc. for $867.7 million (65.3x revenue), or 27$ per share. Dova acquires, develops and commercializes drug candidates for diseases such as thrombocytopenia, a condition that leaves an individual with a low blood platelet count. Its […]

Swedish Orphan Drug Maker Moves into the U.S.

Ready or not, here comes Swedish Orphan Biovitrum AB (STO: SOBI). The company recently paid $1.5 billion to AstraZeneca (NYSE: AZN) in a double-sided deal. First, it’s acquiring the perpetual U.S. rights to Synagis (palivizumab), which prevents serious lower respiratory tract infections (LRTI) caused by FSV in high-risk infants. The other side of the deal […]